Increasing discovery & development success
BIOTECH | PHARMA
Bioanalytical
Strategy
& Outsourcing
Optimizing discovery & development operations
and activities.
Advisory service on non-/clinical study plans
Improving the basis for decision making (PK, PD, TK, biomarkers, immunogenicity).
Support of regulatory submissions and handling of queries
Strengthening the position towards regulatory authorities (PK, PD, TK, biomarkers, immunogenicity).
Dr. Anke Domdey
Who We Are
ANDO was founded by Anke Domdey (MSc, PhD) who has been in the biotech/ pharma consultancy business for 10+ years after she had leading positions in Bio-/ Pharma including Bayer, Boehringer Ingelheim and LEO Pharma for 20+ years.
Anke is a drug/ vaccine candidate selection and development expert with specific expertise in bioanalytical strategy development and outsourcing of bioassay development & validation fit-for-purpose or according to regulatory and GLP/GCP guidelines (LC/MS, LBA, functional assays).
ANDO
Consultancy company supporting Biotech and Pharma in advancing drug/ vaccine discovery and development
Ando focus is on bioanalytical strategy development and outsourcing. Further, Ando gives advice on non-/clinical study plans and regulatory submissions/ queries with respect to bioanalytical outcome measures.
Bioanalytical Outsourcing
GLP/GCP compliance
Drug Development
Pharmacokinetics
Biomarkers
Consultancy
INTEGRATED EXPERTISE
Case descriptions
LINK Medical Research AS and Ando ApS have signed a Letter of Intent to collaborate in the business segment early drug/ vaccine development for the purpose of providing extended knowledge to LINK Medical clients
Link Medical is a Northern European full-service clinical CRO providing project management and product development services for the pharmaceutical and medical device industry. In September 2018
...Ando supports VAR2 Pharmaceuticals in advancing preclinical development of VAR2CSA-toxin-conjugate
VAR2 Pharmaceuticals is a privately held biotechnology company engaged in the design and development of proprietary therapeutic proteins targeting cancer-specific carbohydrate structures for
...Clients
